The processing of complex oral solids, from formulation design to scale-up and manufacturing is fraught with several challenges; as a result, drug developers are increasingly relying on service providers that offering integrated capabilities in this domain

 

Roots Analysis is pleased to announce the publication of its recent study, titled, Oral Solid Dosage Manufacturing Market, 2023-2035”.

 

The report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different regions. Amongst other elements, the report includes:

§  An executive summary of the insights captured during our research, offering a high-level view on the current state of oral solid dosage contract manufacturing market and its likely evolution in the mid-long term.

§  A general overview of oral solid dosage contract manufacturing, highlighting details on the various types and components of oral solid dosage forms. Additionally, it presents information on the oral solid dosage (OSD) manufacturing process. Further, it highlights the emerging trends in OSD manufacturing domain, featuring information on the commonly outsourced manufacturing operations. The chapter concludes with a discussion on key considerations while selecting a CDMO partner, the affiliated risks and future perspectives of growth in this domain.

§  A detailed assessment of the overall market landscape of the companies offering oral solid dosage contract manufacturing services, based on several relevant parameters.

§  A detailed competitiveness analysis of oral solid dosage contract manufacturing service providers based on supplier strength and service strength.

§  A detailed region-wise analysis of the capabilities of oral solid dosage contract manufacturers established across the key geographical regions (North America, Europe, Asia-Pacific and Rest of the World), based on several relevant parameters.

§  Elaborate profiles of key players engaged in the contract manufacturing of oral solids (shortlisted based on strength of service portfolio).

§  An insightful make versus buy framework, highlighting the various factors that need to be taken into consideration by oral solid dosage drug developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO or CDMO partner.

§  A detailed analysis of the recent expansions (since 2018) undertaken by various service providers in order to augment their respective oral solid dosage contract manufacturing portfolios, based on a several relevant parameters.

§  An estimate of the global installed capacity (in terms of number of oral solid units and volume of API) for the manufacturing of oral solids, presenting a holistic view of the supply-side of the market.

§  An informed estimate of the annual clinical and commercial demand for oral solids (in terms of volume of API), across key geographical regions and therapeutic areas.

§  A detailed analysis of the total cost of ownership for an oral solid dosage contract manufacturing service provider, highlighting the expenses associated with the establishment and maintenance of an oral solid dosage manufacturing facility, over a period of 20 years.

§  A discussion on various guidelines laid down by major regulatory bodies, across different countries, featuring an elaborative assessment of CMOs engaged in this domain, along with information on several relevant parameters.

§  A case study on the current market landscape of taste masking service providers, providing information on their year of establishment, company size, location of headquarters, services offered and several other relevant parameters.

§  A case study on the overall market landscape of bioavailability enhancement service providers, based on several relevant parameters.

The financial opportunity within the global bioreactors and fermenters market has been analyzed across the following segments:

  • Type of Finished Dosage Form

§  Tablets

§  Capsules

§  Granules

§  Powders

§  Others

 

  • Type of Packaging

§  Bottles

§  Blisters

§  Sachets

§  Strips

§  Stick Packs

 

  • Scale of Operation

§  Pre-commercial

§  Commercial

 

  • Company Size

§  Small

§  Mid-sized

§  Large

§  Very Large

 

  • Therapeutic Areas

§  Oncological Disorders

§  Cardiovascular Disorders

§  Metabolic Disorders

§  Neurological Disorders

§  Genetic Disorders

§  Respiratory Disorders

§  Immunological Disorders

§  Other Disorders

 

  • Key Geographical Regions

§  North America

§  Europe

§  Asia-Pacific

§  Latin America

§  Middle East and North Africa

 

The report includes profiles of key players (listed below) engaged in offering contract manufacturing services for oral solids; each profile includes a brief overview of the company, along with information on its financial information (if available), service portfolio, recent developments and an informed future outlook.

§  Aenova

§  Alcami

§  Almac

§  Cambrex

§  Catalent

§  Hetero Drugs

§  Ind-Swift

§  Lonza

§  Rubicon Research

 

To view more details on this report, click on the link

https://www.rootsanalysis.com/reports/oral-solid-dosage-manufacturing-market.html

 

News article

Non-viral Drug Delivery Systems Market

 

Learn from experts:  do you know about these emerging industry trends?

mRNA Synthesis: Manufacturing Process of Modern Revolutionary Molecule

TIL Therapies: A New Paradigm in Cancer Treatment

 

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

 

Contact:

Ben Johnson

+1 (415) 800 3415

Ben.johnson@rootsanalysis.com